Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

PHASE2TerminatedINTERVENTIONAL

Enrollment

111

Participants

Timeline

Start Date

March 1, 2007

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2015

Conditions

Neuroendocrine (NE) Tumors

Interventions

DRUG

Capecitabine (Xeloda)

Capecitabine (1650 mg/m2/day) was administered for two weeks from the start of each PRRT cycle.

DRUG

177Lu-DOTATATE

Patients with advanced somatostatin receptor positive GEP NET or bronchopulmonary NET were included to receive four cycles of 7.4 GBq 177Lu-Dotatate.